NovaBay® Pharmaceuticals, Inc. (NYSE: NBY), a medicinal company concentrating on increasing its attendance in the eye and skincare marketplace, proclaims the obtainability of i-Chek Floodlit Eye Inspection Glass on Amazon. i-Chek is a distinctive moveable, lightweight, handheld lighted glass containing 10x exaggeration that is precisely intended for the at-home exact graphic purpose and high exaggeration of the eyes, eyelashes, and eyelids.
“i-Chek is the perfect cohort merchandise to Avenova, our leading antimicrobial top and lash sprig, as long as a modified before-and-after appearance at the efficiency of Avenova,” said Justin Hall, President and CEO of NovaBay Pharmaceuticals. Different uses for i-Chek comprise help with removing scleral contact lens foams and contact insertion misalignments and aiding to stop eye contagions when eliminating maquillage. i-Chek sorts four LED ECO bulbs for more than 15,000 hours of usage and a hard-wearing transport case. The creation is obtainable on Amazon.com and Avenova.com for $29.99.
In other news, the company reported its first-quarter financial results.
Net produce income for the first quarter of 2021 was $1.8 million, compared to $1.9 million for the first quarter of 2020, with the variance due to income generated from yields other than Avenova in 2020. Avenova’s income for the first quarter of 2021 was $1.6 million, up from $1.5 million for 2020. The upsurge imitates the sustained higher number of OTC units sold, partly counterbalanced by reducing the number of net units sold through drugstore networks.
Deals and promotion expenditures for the first quarter of 2021 were $1.7 million, likened to $1.6 million for the first quarter of 2020. Overall and secretarial expenditures for the first quarter of 2021 were $1.2 million, likened to $1.3 million for 2020.
Operating loss for the first quarters of 2021 and 2020 was unaffected at $1.5 million.
Net loss for the first quarter of 2021 was $1.5 million, or $0.04 per share, likened with a net loss for the first quarter of 2020 of $1.6 million, or $0.06 per share.